Evommune (EVMN) — Scientific Deep Dive for EVO756, EVO301 and Pipeline Products
Two Shots on Goal: A Mast-Cell Switch Oral and a Tissue-Diving IL-18 Trap
Executive Summary
Evommune is a Phase 2 inflammation play with two genuinely differentiated mechanisms: EVO756, an oral small-molecule antagonist of MRGPRX2 (a GPCR sitting on the same wire that connects mast cells to sensory neurons, fired by neuropeptides like Substance P and PACAP), and EVO301, a half-life-extended IL-18 binding protein fusion (~65 kD, anti-albumin Fab tether) designed to neutralize IL-18 systemically and reach tissue. Both are licensed (EVO756 from Dermira/Lilly, EVO301 from AprilBio), both are in Phase 2b prep or active execution, and the company is sitting on a $307M war chest with three near-term Phase 2b readouts supporting an expected cash runway through 2028. Stocktitan
The Bull Case. If EVO756 lands a UAS7=0 response rate above ~25% in moderate-to-severe CSU at week 12 in the Phase 2b (June 2026 readout), it could become the only oral mast-cell mechanism with a clean safety profile competing in a market projected to grow well past $1B as Xolair, Dupixent, and Rhapsido fail to satisfy ~450K antihistamine-refractory patients. The 12-month average analyst price target of ~$44 from 10 analysts implies ~60% upside, and HC Wainwright’s $50 target signals what a clean Phase 2b CSU readout could do. EVO301 adds a second leg: Phase 2a EASI activity at 12 weeks is statistically comparable to Dupixent at 16 weeks despite only two doses — that’s a credible best-in-class biologic shot in a $50B+ projected AD market. M&A optionality is real; AbbVie, Sanofi, Lilly, and Novartis all need new I&I mechanisms.
The Bear Case. Both lead assets are licensed, not owned — royalty stacks (mid-single to low-tens-digit on EVO756 worldwide sales) and milestone obligations (up to $240M sales milestones on EVO756 alone to Dermira) compress equity economics. The Phase 2 CIndU readout was 30 patients, open-label, within-patient controlled — encouraging but barely powered, and two patients in the 300 mg QD arm had transaminase elevations >10× ULN that the company attributed to “confounding factors.” The CSU shark tank just got crowded: Rhapsido (remibrutinib) was approved September 2025 with ~30% UAS7=0 at week 12 and Celldex’s barzolvolimab posted 51% UAS7=0 at week 12 with Phase 3 readout coming Q4 2026 — that’s a brutal external benchmark. EVO756 is studying doses up to only 150 mg daily in Phase 2b after Phase 2 used 300 mg QD / 50 mg BID — the dose-down narrative needs to hold. And EVO301 needs a subcutaneous Phase 2b initiation in mid-2027, which is a long wait against accumulating IL-18 competition. Cash runway through 2028 is just through 2028 — a Phase 3 raise is coming, the only question is at what price.
Bottom Line. Pristine science, two real mechanisms, top-tier smart money on the cap table (EQT, RA Capital, Pivotal, Andera, Nan Fung), but the equity is licensed-and-leveraged with a binary Phase 2b CSU readout in roughly four weeks. Tradeable for catalyst, long-term thesis requires both CSU and AD to print.
Catalyst Calendar & Financial Runway
Upcoming Catalysts (next 12–18 months)
